Gum Arabic protects the rat heart from ischemia/reperfusion injury through anti-inflammatory and antioxidant pathways.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Gum Arabic*/pharmacology ; Myocardial Reperfusion Injury*/metabolism; Animals ; Rats ; Anti-Inflammatory Agents/pharmacology ; Antioxidants/pharmacology ; Creatine Kinase/metabolism ; Infarction ; Interleukin-10 ; Interleukin-6 ; Lactate Dehydrogenases ; Myocytes, Cardiac/metabolism ; Oxidants ; Rats, Wistar ; Superoxide Dismutase/metabolism ; Tumor Necrosis Factor-alpha

Gum Arabic (GA) is a plant exudate with antioxidant and anti-inflammatory effects. GA has shown promise in protection from and treatment of kidney failure, however, its role in the protection of the heart from ischemia and reperfusion (I/R) has not been investigated. This study investigated the antioxidant and anti-inflammatory effects of Gum Arabic (GA) in the protection of the heart against ischemia/reperfusion (I/R) injury. Langendorff-perfused Wistar rat hearts were divided into seven groups. One group which was subjected to I/R with no other treatment served as the control group. The second group was subjected to buffer perfusion with no ischemia (sham group). The third group was perfused with GA in the absence of ischemia (sham + GA). The rest of the hearts were isolated from rats that had been treated with GA for 4 or 2 weeks in the drinking water, or GA that had been infused intravenously 2 h before sacrifice or added to perfusion buffer at reperfusion. Hemodynamics data were digitally computed; infarct size was measured using 2,3,5-triphenyltetrazolium chloride (TTC) staining and cardiomyocyte injury was assessed by quantifying creatine kinase (CK) and lactate dehydrogenase (LDH) enzymes. The total oxidants (TOS) and antioxidants (TAS), superoxide dismutase (SOD) and pro- and anti-inflammatory cytokines levels were estimated by ELISA. GA treatment for 2 weeks, 4 weeks or 2 hours before sacrifice resulted in a significant (P < 0.05) improvement in cardiac hemodynamics and reduction in infarct size and cardiac enzyme levels compared to respective controls. However, GA administration at the time of reperfusion did not protect the hearts against I/R injury. Furthermore, GA treatment decreased the pro-inflammatory and anti-inflammatory cytokines levels. The levels of TOS in the effluent were significantly decreased (P < 0.05) and SOD levels were significantly (P < 0.05) increased by GA administration. GA protected the heart against I/R injury when administered for 2 or 4 weeks or when infused 2 hours before sacrifice. GA treatment decreased the total oxidants levels, the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 protein levels and increases SOD and anti-inflammatory cytokine IL-10 protein levels.
(© 2022. The Author(s).)

Cardiovasc J Afr. 2013 Jul;24(6):208-12. (PMID: 24217260)
Lipids Health Dis. 2018 Mar 20;17(1):56. (PMID: 29558953)
Int J Mol Sci. 2018 Jan 31;19(2):. (PMID: 29385043)
Food Chem Toxicol. 2009 Jan;47(1):1-8. (PMID: 18672018)
Ren Fail. 2004 Jan;26(1):1-3. (PMID: 15083914)
Clin Biochem. 2005 Dec;38(12):1103-11. (PMID: 16214125)
Cardiovasc Drugs Ther. 2009 Aug;23(4):327-31. (PMID: 19466533)
PLoS One. 2013;8(2):e55242. (PMID: 23383316)
Beijing Da Xue Xue Bao Yi Xue Ban. 2007 Dec 18;39(6):570-5. (PMID: 18087543)
Med Princ Pract. 2011;20(6):495-6. (PMID: 21986004)
Chest. 2000 Aug;118(2):503-8. (PMID: 10936147)
J Heart Lung Transplant. 2015 Nov;34(11):1471-80. (PMID: 26140808)
Nat Rev Rheumatol. 2011 May 31;7(7):399-408. (PMID: 21629241)
Cell. 2017 Apr 20;169(3):510-522.e20. (PMID: 28431249)
Life Sci. 2016 Feb 1;146:163-73. (PMID: 26792059)
Biomolecules. 2019 Jan 11;9(1):. (PMID: 30641998)
Am J Physiol Heart Circ Physiol. 2016 Jan 1;310(1):H104-12. (PMID: 26519026)
Cell Physiol Biochem. 2014;34(3):818-28. (PMID: 25171124)
Circ Res. 2018 Jun 22;123(1):100-106. (PMID: 29592957)
Circulation. 2012 Dec 4;126(23):2739-48. (PMID: 23129601)
J Nutr. 2011 Jul;141(7):1318-25. (PMID: 21562241)
J Mol Cell Cardiol. 2012 Apr;52(4):822-31. (PMID: 21889943)
J Cardiovasc Transl Res. 2012 Oct;5(5):727-34. (PMID: 22826102)
Heart. 2002 Mar;87(3):201-4. (PMID: 11847151)
Phytomedicine. 2011 Oct 15;18(13):1176-80. (PMID: 21741228)
Circulation. 2003 Apr 29;107(16):2109-14. (PMID: 12668510)
Circulation. 2001 Sep 18;104(12 Suppl 1):I308-I3. (PMID: 11568074)
Clin Biochem. 2004 Apr;37(4):277-85. (PMID: 15003729)
Front Physiol. 2019 Feb 25;10:53. (PMID: 30858803)
Int J Cardiol. 2013 Sep 30;168(2):934-45. (PMID: 23218570)
Hum Exp Toxicol. 2017 Jan;36(1):62-81. (PMID: 26987350)
BMC Hematol. 2017 Mar 16;17:4. (PMID: 28331623)
Pharmacol Res. 2002 Nov;46(5):445-51. (PMID: 12419649)
Cell Physiol Biochem. 2018;45(6):2293-2304. (PMID: 29550811)
Int J Biol Macromol. 2016 Apr;85:379-85. (PMID: 26772915)
Ren Fail. 2012;34(1):73-82. (PMID: 22017619)
Nat Med. 2018 Aug;24(8):1234-1245. (PMID: 29892064)
Adv Drug Deliv Rev. 2009 Apr 28;61(4):287-9. (PMID: 19306902)
Biochim Biophys Acta. 2009 Jul;1787(7):781-93. (PMID: 19248760)
J Biochem Mol Toxicol. 2002;16(5):254-9. (PMID: 12439867)
ACS Appl Mater Interfaces. 2016 Jan 27;8(3):2423-34. (PMID: 26731614)
Clin Cardiol. 2011 Jul;34(7):410-4. (PMID: 21688276)
Pathophysiology. 2015 Dec;22(4):189-94. (PMID: 26321624)
Exp Clin Cardiol. 2011 Summer;16(2):e5-e10. (PMID: 21747660)
Int J Pharm. 2005 Jul 14;298(1):153-63. (PMID: 15955644)
Essays Biochem. 2010;47:53-67. (PMID: 20533900)
Aust Dent J. 2010 Mar;55(1):65-9. (PMID: 20415914)
Exp Clin Cardiol. 2012 Sep;17(3):95-100. (PMID: 23620695)
BMC Hematol. 2015 Dec 29;15:19. (PMID: 26719803)
Drug Des Devel Ther. 2013 Oct 21;7:1245-52. (PMID: 24174869)

0 (Anti-Inflammatory Agents)
0 (Antioxidants)
EC 2.7.3.2 (Creatine Kinase)
9000-01-5 (Gum Arabic)
130068-27-8 (Interleukin-10)
0 (Interleukin-6)
EC 1.1.- (Lactate Dehydrogenases)
0 (Oxidants)
EC 1.15.1.1 (Superoxide Dismutase)
0 (Tumor Necrosis Factor-alpha)

Date Created: 20221014 Date Completed: 20221104 Latest Revision: 20230105

20231215

PMC9568585

10.1038/s41598-022-22097-0

36241904